Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody
Conditions: Hepatocellular Carcinoma Interventions: Biological: γδ T cells; Drug: PD-1 monoclonal antibody; Drug: targeted drugs Sponsors: Beijing 302 Hospital; Chinese Academy of Medical Sciences; Beijing GD Initiative Cell Therapy Technology Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Cancer & Oncology | Carcinoma | China Health | Clinical Trials | Hepatocellular Carcinoma | Hospitals | Immunotherapy | Liver Cancer | Research